News and Press Releases

Contact Veristat Now


Request A Proposal

Contact Us

Veristat Supports Antibe Therapeutics for Pain and Inflammation Study

November 7, 2018

Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B dose-ranging, efficacy study for their lead drug candidate ATB-346.   The study will run in Canada and is expected to conclude in December 2018.

Read More

Veristat Partners with TRI For Risk-Based Monitoring Technology

November 5, 2018

Veristat Partners with TRI to Provide Centralized and Risk-Based Monitoring Technology to Their Biopharmaceutical Clients

 

Read More

Veristat Strengthens Clinical Operations Capabilities - Acquires Topstone Research

October 1, 2018

Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized Biopharma

Read More

Veristat Congratulates Alnylam on the FDA Approval of ONPATTRO™

August 20, 2018

Continues Collaboration to Provide Regulatory Submission Support for
Additional Patisiran Submissions

 

SOUTHBOROUGH, MA –  August 20, 2018 –   Veristat, a full service Clinical Research Organization (CRO), congratulates Alnylam on the recent FDA approval of ONPATTRO™ (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. 

Read More

Veristat Congratulates Agios on the FDA Approval of TIBSOVO®

August 16, 2018

 The First Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation

 

SOUTHBOROUGH, MA –  August 16, 2018 –   Veristat, a full service Clinical Research Organization (CRO), congratulates Agios on the recent FDA approval of TIBSOVO® (ivosidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test.

Read More

Veristat is Recognized on the Inc. 5000 List of America’s Fastest-Growing Private Companies for the 4th Consecutive Year

August 15, 2018

 Veristat’s Continued Innovation of Its Clinical Development Strategies and Services Allow the Company to Execute High Quality Trials That Reach Regulatory Approval

 

SOUTHBOROUGH, MA –  August 15, 2018 –   Veristat, a full service Clinical Research Organization (CRO), proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States. 

Read More

Veristat Recognized for a Third Consecutive Year on the Inc. 5000 List of America’s Fastest-Growing Private Companies

August 21, 2017

Veristat’s Growth Positively Impacts Our Ability to Help Clients Achieve Regulatory Approval of their Life-Changing and Life-Saving Therapies

SOUTHBOROUGH, MA – August 21, 2017Veristat announced today that it has been recognized for a third consecutive year by Inc. Magazine as one of America’s fastest-growing private companies. Veristat joined the list in 2015.  

Read More

Veristat and AOBiome Establish a Preferred Partnership To Support Ongoing & Impending Clinical Programs

June 19, 2017

SOUTHBOROUGH, MA –  June 19, 2017Veristat, a full service Clinical Research Organization (CRO), announced today that Veristat and AOBiome, a clinical-stage life sciences company advancing patented microbiome-targeted therapies for systemic and local inflammatory conditions, have entered into a Preferred Provider Agreement (PPA). 

Read More

Veristat Congratulates TESARO on the FDA Approval of ZEJULA™

May 30, 2017

SOUTHBOROUGH, MA –  May 30, 2017 –   Veristat, a full service Clinical Research Organization (CRO), congratulates TESARO, Inc. on the approval of ZEJULA™.  

Read More

Veristat Acknowledged on Boston Business Journal’s “Fast 50” List for a Second Consecutive Year

May 15, 2017

Ranked as one of the Top 50 Fastest Growing Private Companies in Massachusetts

Read More